| Autor: |
David A. Axelrod, Wisit Cheungpasitporn, Suphamai Bunnapradist, Mark A. Schnitzler, Huiling Xiao, Mara McAdams-DeMarco, Yasar Caliskan, Sunjae Bae, JiYoon B. Ahn, Dorry L. Segev, Ngan N. Lam, Gregory P. Hess, Krista L. Lentine |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Kidney Medicine, Vol 4, Iss 1, Pp 100377- (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2590-0595 |
| DOI: |
10.1016/j.xkme.2021.08.012 |
| Popis: |
Rationale & Objective: Posttransplant diabetes mellitus (DM) after kidney transplantation increases morbidity and mortality, particularly in older and obese recipients. We aimed to examine the impact of immunosuppression selection on the risk of posttransplant DM among both older and obese kidney transplant recipients. Study Design: Retrospective database study. Setting & Participants: Kidney-only transplant recipients aged ≥18 years from 2005 to 2016 in the United States from US Renal Data System records, which integrate Organ Procurement and Transplantation Network/United Network for Organ Sharing records with Medicare billing claims. Exposures: Various immunosuppression regimens in the first 3 months after transplant. Outcomes: Development of DM >3 months-to-1 year posttransplant. Analytical Approach: We used multivariable Cox regression to compare the incidence of posttransplant DM by immunosuppression regimen with the reference regimen of thymoglobulin (TMG) or alemtuzumab (ALEM) with tacrolimus + mycophenolic acid + prednisone using inverse propensity weighting. Results: 12.7% of kidney transplant recipients developed posttransplant DM with higher incidences in older (≥55 years vs |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
